Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

The White House has blamed the Biden administration for failing to advance domestic production or fill the reserve.

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by the accumulation of scar tissue in the ...

Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being ...

This podcast tackles how pharma can drive better commercial packaging collaborations during the transition from clinical to ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the US EoE market ...

Concerns around Ixchiq's safety profile in elderly individuals continue as travel-related chikungunya cases increase in the ...

Apertura Gene Therapy has entered several licensing agreements to advance CNS treatments using its TfR1 CapX technology.

Amphastar has signed an exclusive license agreement with Anji for the development, production, use and commercialisation of 3 ...